

# Index

## **ABBREVIATED NEW DRUG SUBMISSION (ANDS)**

Informational requirements, **1:3**  
Supplemental, **1:7**

## **ACCESS TO INFORMATION ACT**

New drug approval process, **1:4**

## **ADVERTISING LIFE SCIENCES PRODUCTS**

Generally, **3:1 et seq.**  
Advertising Standards Canada (ASC), **3:3**  
Consumer advertising  
    generally, **3:4**  
    natural health products, **3:4**  
    non-prescription drugs, **3:4**  
    prescription drugs, **3:4**  
Definitions and classifications, **3:2**  
False, misleading, deceptive advertising,  
    **3:2**  
Health Canada, **3:3**  
Introduction, **3:1**  
Labelling requirements, (prescription,  
    non-prescription, NHPs), **3:4**  
Medical devices, **3:4**  
Regulatory control, **3:3**  
Vaccines, **3:4**

## **ADVERTISING STANDARDS CANADA (ASC)**

Generally, **3:3**

## **BIOLOGIC AND GENERIC THERAPIES DIRECTORATE (BGTD)**

Generally, **1:5**  
Regulatory control, **3:3**  
Submissions and review, **1:8**

## **BIOLOGICS**

Regulation of products and, **1:5**

## **CANADIAN ASSOCIATION OF MEDICAL PUBLISHERS (CAMP)**

Marketing to healthcare professionals, **3:5**

## **CANADIAN INTELLECTUAL PROPERTY OFFICE (CIPO)**

Generally, **6:1 et seq.**  
Trademarks and, **10:1**

## **CANADIAN INTERNET REGISTRATION AUTHORITY (CIRA)**

Domain names and, **10:2**

## **CANADIAN MEDICAL ASSOCIATION**

Marketing to healthcare professionals, **3:5**  
Provincial medical associations, **3:5**

## **CANNABIS**

Cannabis Act, **2:1 et seq.**  
Drugs containing cannabis, **2:3**  
    advertising and promotion, **2:3**  
Importation and exportation of, **2:5**  
Medical cannabis  
    generally, **2:2**  
    access to, **2:2**  
    advertising and promotion, **2:2**  
    licence for sale of cannabis, **2:2**  
    packaging and labelling, **2:2**  
    personal possession limits, **2:2**  
Overview of access to cannabis, **2:1**  
Regulation of products, **2:1 et seq.**  
Test kits, **2:4**

## **CLINICAL TRIAL APPLICATION (CTA)**

Amendments, of, **1:9**  
Regulation of products, **1:9**

## **CLINICAL TRIALS**

Generally, **1:9**  
Human subjects  
    generally, **1:12**  
    authorization, **1:12**  
    sponsor obligations, **1:12**  
    suspension or cancellation, **1:12**  
Natural health products, **1:12**

## **COMPETITION ACT**

Advertising and labelling, **3:1, 3:4**

**CONTROLLED DRUGS AND  
SUBSTANCES ACT**Regulation of products, **1:1****CONVENTION ON BIOLOGICAL  
DIVERSITY (CBD)**Canada's international obligations, **5:5****DATA PROTECTION**Generally, **9:1 et seq.**Canada, in, **9:4**Canada's international obligations, **9:2**Other countries, in, **9:3****DISPUTE SETTLEMENT  
UNDERSTANDING (DSU)**Mechanisms under TRIPS and NAFTA,  
**5:6****DOMAIN NAMES**

See also TRADEMARKS

Generally, **10:9**Dot-ca, **10:10**Legal recourse, **10:11****DRUG IDENTIFICATION NUMBER  
(DIN)**Marketing approval, **1:3****DRUGS**Biologics, **1:5**Changes to new drugs once approved, **1:7**Clinical trials, **1:9**Drug-medical device combination  
products, **1:11**Drugs containing cannabis, **2:3**  
advertising and promotion, **2:3**Genetic therapies, **1:5**

Marketing approval

generally, **1:3**drug identification number (DIN), **1:3**notice of compliance, **1:3**

standards for establishments

generally, **1:3**establishment licences, **1:3**good manufacturing practices,  
application of, **1:3**

Natural health products (NHP)

generally, **1:12**

clinic trials involving human subjects

generally, **1:12**authorization, **1:12**sponsor obligations, **1:12****DRUGS—Cont'd**Natural health products (NHP)—Cont'd  
clinic trials involving human subjects  
—Cont'dsuspension or cancellation, **1:12**good manufacturing practices, **1:12**history of NHP legislation, **1:12**labelling and packaging, **1:12, 3:4**

product licences

generally, **1:12**amending product licence, **1:12**application for, **1:12**cancellation or suspension, **1:12**reporting obligations on licensees,  
**1:12**scope of NHP legislation, **1:12**site licences, **1:12**New drug approval process, **1:4**

Non-prescription drugs

advertising and promotion, **3:4**labelling requirements, **3:4**Post-market surveillance, **1:6**

Prescription drugs

labelling requirements, **3:4**Radiopharmaceuticals, **1:5**Regulation of products, **1:1 et seq.**Sale of, **1:2**Submission and review process, **1:8**Supplemental abbreviated new submis-  
sions, **1:7, 5:7****FOOD AND DRUG REGULATIONS**

Clinical trials

amendment to application, **1:9**application, **1:9**Data protection and, **9:4**

Notice of Compliance (NOC) Regulations

generally, **8:3**framework, **8:3**policy concerns, **8:2**Patent listing submission, nature of, **8:5****FOOD AND DRUGS ACT**

See also DRUGS

Biologics, **1:5**Clinical trials, **1:9**Genetic therapies, **1:5**Medical devices, **1:10**Radiopharmaceuticals, **1:5**Regulation of products, **1:1 et seq.**

## INDEX

### **FOOD AND DRUGS ACT—Cont'd**

- Regulations under
  - clinical trials
    - amendment to application, **1:9**
    - application, **1:9**
  - data protection and, **9:4**
  - framework, **8:3**
  - policy concerns, **8:2**
- Notice of Compliance (NOC) Regulations, **8:3**
- patent listing submission, nature of, **8:5**

### **GENERAL AGREEMENT ON TARIFFS AND TRADE**

- Canadian international obligations, **5:2, 9:2**

### **HEALTH CANADA**

- Biologic and Genetic Therapeutics Directorate (BGTD), **3:3**
- Biologics, **1:5**
- Genetic therapies, **1:5**
- Health Products and Food Branch, **3:3**
- Licensing service division, **1:8**
- Marketed Health Products Directorate, **3:3**
- Radiopharmaceuticals, **1:5**
- Regulatory control, advertising life science products, **3:3**
- Therapeutic Products Directorate, **1:8, 1:11**

### **HEALTH CARE PROFESSIONALS**

- Marketing, to
  - generally, **3:5**
  - Innovative Medicines Canada (IMC), **3:5**
  - pharmaceutical advertising advisory board (PAAB), **3:5**
  - provincial medical associations, **3:5**

### **INCOME TAX ACT**

- Generally, **13:1 et seq.**

### **INNOVATIVE MEDICINES CANADA (IMC)**

- Generally, **3:5**

### **INTERNATIONAL TRADE OBLIGATIONS**

- Generally, **5:1**
- Canada's previous obligations
  - Berne Convention for the Protection of Literary and Artistic Works, **5:2**

### **INTERNATIONAL TRADE**

#### **OBLIGATIONS—Cont'd**

- Canada's previous obligations—Cont'd
  - Canada-US Free Trade Agreement, **5:2**
  - General Agreement on Tariffs and Trade, **5:2**
  - Paris Convention for the Protection of Industrial Property, **5:2**
- CETA, **5:7**
- Dispute settlement mechanisms
  - generally, **5:6**
  - NAFTA, **5:6, 9:2**
  - TRIPS, **5:6, 9:2**
- Implementation in Canada
  - generally, **5:4**
  - Bill C-22, **5:4**
  - Bill C-91, **5:4**
  - legislation, **5:4**
- Life sciences products, relevant provisions re
  - basic obligations, **5:5**
  - data protection, **5:5**
  - enforcement, **5:5**
  - exceptions, limited, **5:5**
  - licensing, compulsory, **5:5**
  - non-discrimination, **5:5**
  - patentability, **5:5**
  - patent protection, term of, **5:5**
  - patent rights, **5:5**
- Negotiations
  - NAFTA, **5:3**
  - TRIPS, **5:3**
- Trans-Pacific Partnership (TPP), **5:8**

### **LICENCES**

- Establishment
  - drugs, **1:3**
  - medical devices, **1:10**
- Product
  - generally, **1:12**
  - amending product licence, **1:12**
  - application for, **1:12**
  - cancellation or suspension, **1:12**
  - reporting obligations on licensees, **1:12**
- Site licences, **1:12**

### **MARKETED HEALTH PRODUCTS DIRECTORATE**

- Marketing, advertising and labelling, **3:3**

**MARKETING**

See also **ADVERTISING AND PROMOTION OF LIFE SCIENCES PRODUCTS**

Healthcare professionals, to generally, **3:5**  
 Innovative Medicines Canada (IMC), **3:5**  
 pharmaceutical advertising advisory board, **3:5**  
 provincial medical associations, **3:5**  
 Labelling requirements  
 natural health products, **1:12**  
 non-prescription drugs, **3:4**  
 prescription drugs, **3:4**

**MEDICAL CANNABIS**

See also **CANNABIS**  
 Access to, **2:2**  
 Advertising and promotion, **2:2, 3:4**  
 Licence for sale of cannabis, **2:2**  
 Packaging and labelling, **2:2**  
 Personal possession limits, **2:2**

**MEDICAL DEVICES**

Generally, **1:10**  
 Advertising and promotion, **3:4**  
 Approval to sell in Canada, **1:10**  
 Establishment licences, **1:10**  
 Investigational testing, **1:10**  
 Reporting obligations, **1:10**  
 Software, **1:11.50**  
 Special access, **1:10**

**NATURAL HEALTH PRODUCTS (NHP)**

Generally, **1:12**  
 Clinic trials involving human subjects generally, **1:12**  
 authorization, **1:12**  
 sponsor obligations, **1:12**  
 suspension or cancellation, **1:12**  
 Good manufacturing practices, **1:12**  
 History of NHP legislation, **1:12**  
 Labelling and packaging, **1:12**  
 Product licences  
 generally, **1:12**  
 amending product licence, **1:12**  
 application for, **1:12**  
 cancellation or suspension, **1:12**  
 reporting obligations on licensees, **1:12**  
 Scope of NHP legislation, **1:12**

**NATURAL HEALTH PRODUCTS (NHP)—Cont'd**

Site licences, **1:12**

**NEW DRUG SUBMISSIONS**

Abbreviated, **5:7**  
 Access to Information Act, **1:4**  
 Patent listing and, **8:5**

**NOTICE OF COMPLIANCE**

See also **PATENTED MEDICINES (NOC REGULATIONS)**  
 Notice of compliance regulations  
 generally, **8:1**  
 framework of, **8:3**  
 policy concerns addressed by, **8:2**

**PATENTABILITY REQUIREMENTS**

See also **PATENT LAW**  
 Double patenting, **6:3**  
 Life forms, patentability of  
 generally, **6:5**  
 Abitibi case, **6:5**  
 deposit of biological materials, **6:5**  
 Harvard Mouse case, **6:5**  
 Monsanto case, **6:5**  
 Novelty and inventiveness, **6:3**  
 Overlapping subject matter, **6:3**  
 Sufficiency of specification, **6:3**  
 Utility, **6:3**

**PATENTED MEDICINES (NOC REGULATIONS)**

Addressing listed patents  
 generally, **8:7**  
 confidentiality, **8:7**  
 invalidity allegations, **8:7**  
 non-infringement allegations, **8:7**  
 notice of allegation  
 generally, **8:7**  
 other challenges, **8:7**  
 sufficiency of, **8:7**  
 Certificates of supplementary protection  
 generally, **8:6**  
 CSP term, **8:6**  
 eligibility for, **8:6**  
 Initiating proceedings  
 generally, **8:8**  
 abuse of process, **8:8**  
 appealing a ruling, **8:9**  
 burden of proof, **8:8**  
 indirect infringement, **8:8**

**PATENTED MEDICINES (NOC REGULATIONS)—Cont'd**

- Initiating proceedings—Cont'd
  - on or after September 21, 2017, **8:8**
  - prior to September 21, 2017, **8:8**
  - Section 8 damages, **8:10**
  - summary dismissal, **8:8**
  - time period, **8:8**
- Notice of compliance regulations
  - generally, **8:1**
  - framework of, **8:3**
  - policy concerns addressed by, **8:2**
- Patent listing
  - generally, **8:5**
  - challenging, **8:5**
  - maintenance of patent register, **8:5**
  - nature of submission, **8:5**
  - timing requirements, **8:5**

**PATENT ENFORCEMENT**

- Generally, **7:1**
- Defences to infringement
  - generally, **7:6**
  - non-inducement to infringe, **7:6**
  - non-infringement
    - generally, **7:6**
    - invalidity, **7:6**
    - licence, **7:6**
- Experimental testing, **7:8**
- Expert witnesses
  - generally, **7:7**
  - definition of, **7:7**
  - qualifications of, **7:7**
  - role of, **7:7**
- Infringement
  - generally, **7:4**
  - checklist before commencing infringement suit
    - generally, **7:5**
    - additional circumstances, **7:5**
    - assessment, **7:5**
    - basic information, **7:5**
    - relief sought, **7:5**
  - defences to, **7:6**
  - definition, **7:4**
  - proof of, **7:4**
  - types, **7:4**
- Monopoly rights
  - generally, **7:2**
  - actual rights, **7:2**

**PATENT ENFORCEMENT—Cont'd**

- Monopoly rights—Cont'd
  - duration of rights, **7:2**
  - remedies
    - generally, **7:2**
    - accounting of profits, **7:2**
    - damages, **7:2**
    - delivery up, **7:2**
    - injunctions, **7:2**
- Patent infringer, proceedings against
  - generally, **7:3**
  - litigation, **7:3**
- litigation
  - checklist before commencing, **7:5**
- pre-litigation
  - generally, **7:3**
  - alternative dispute resolution, **7:3**
  - cease and desist letter, **7:3**

**PATENT INFRINGEMENT**

- See also **PATENT ENFORCEMENT**
- Generally, **7:4**
- Checklist before commencing infringement suit
  - generally, **7:5**
  - additional circumstances, **7:5**
  - assessment, **7:5**
  - basic information, **7:5**
  - relief sought, **7:5**
- Defences to
  - generally, **7:6**
  - non-inducement to infringe, **7:6**
  - non-infringement
    - generally, **7:6**
    - invalidity, **7:6**
    - licence, **7:6**
- Definition, **7:4**
- Proof of, **7:4**
- Types, **7:4**

**PATENT LAW**

- Generally, **6:1 et seq.**
- DNA, RNA, and antibodies, patentability of
  - generally, **6:6**
  - antibodies, **6:6**
  - background, **6:6**
  - disclosure, **6:6**
- Fertilized eggs, patentability of, **6:7**

**PATENT LAW—Cont'd**

- Infringement
  - see also PATENT
  - INFRINGEMENT defences to
    - defences to, **7:6**
    - invalidity, **7:6**
    - licence, **7:6**
    - non-inducement to infringe, **7:6**
    - non-infringement, **7:6**
- Life forms, patentability of
  - generally, **6:5**
  - Abitibi case, **6:5**
  - deposit of biological materials, **6:5**
  - Harvard Mouse case, **6:5**
  - Monsanto case, **6:5**
- Organ and tissues, **6:7**
- Patentability requirements
  - generally, **6:3**
  - double patenting, **6:3**
  - novelty and inventiveness, **6:3**
  - overlapping subject matter, **6:3**
  - sufficiency of specification, **6:3**
  - utility, **6:3**
- Patent application
  - prosecution, of, **6:2**
- Prosecution of patent application
  - generally, **6:2**
  - action, final, **6:2**
  - allowance and issuance, **6:2**
  - amendment after allowance, **6:2**
  - appeals, **6:2**
  - convention priority, **6:2**
  - entity status, **6:2**
  - examination of application, **6:2**
  - filing prior art, **6:2**
  - maintenance fees, **6:2**
  - national entry, **6:2**
  - official filing date, **6:2**
  - ownership, **6:2**
  - publication, **6:2**
  - public disclosure restrictions, **6:2**
  - re-examination of patents, **6:2**
  - reissue and disclaimer, **6:2**
  - request for examination, **6:2**
- Stem cells, patentability of, **6:7**

**PHARMACEUTICAL ADVERTISING  
ADVISORY BOARD (PAAB)**

- Marketing to healthcare professionals, **3:5**

**PHARMACEUTICAL PRICING AND  
MARKET ACCESS**

- National Pharmacare Program, **4:8**
- Patented medicine prices review board
  - generally, **4:1 to 4:8**
  - compendium of guidelines, policies and procedures, **4:3**
  - constitutionality, **4:5**
  - mandate, jurisdiction and process, **4:4**
  - mandatory reporting requirements, **4:6**
  - provincial pricing, **4:7**
  - provincial pricing issues, **4:8**
  - statutory framework
    - generally, **4:2**
    - excessive pricing provisions, **4:1 to 4:8**
    - process provisions, **4:1 to 4:8**
- Reporting requirements, **4:1 to 4:8**

**PRIVACY LAW**

- Generally, **12:1 et seq.**
- Breaches and breach response, **12:6**
- Compliance, **12:7**
- Fundamental principles, **12:3**
- Human subject research, **12:5**
- Legislative framework, **12:2**
- Organizational privacy vigilance, **12:7**
- Personal health information, **12:4**

**PRODUCT LIABILITY**

- Generally, **11:1 et seq.**
- Causation, **11:3**
- Class actions, **11:6**
- Contract and statutory claims, **11:5**
- Damages, **11:7**
- Innovator liability, generic drug sales, **11:4**
- Limitation periods, **11:8**
- Negligence claims
  - generally, **11:2**
  - design defect claim, **11:2**
  - failure to warn claim, **11:2**
  - manufacturing defect claim, **11:2**
- Procedural issues, **11:9**
- Québec law principles, **11:10**

**SOFTWARE**

- Medical device, **1:11.50**

INDEX

**SUPPLEMENTAL ABBREVIATED  
NEW DRUG SUBMISSION  
(SANDS)**

Generally, **1:7, 5:7**

**TAX ISSUES**

Generally, **13:1**

Goods and Services Tax (GST), **13:5**

Harmonized Sales Tax (HST), **13:5**

Québec Sales Tax (QST), **13:5**

Scientific research and experimental  
development  
generally, **13:2**

advancement, **13:2**

content, **13:2**

tax credits, **13:2**

uncertainty, **13:2**

Transfer pricing, **13:3**

Withholding tax, **13:4**

**THERAPEUTIC PRODUCTS  
DIRECTORATE (TPD)**

See also HEALTH CANADA

**THERAPEUTIC PRODUCTS  
DIRECTORATE (TPD)—Cont'd**  
Generally, **1:8, 1:11**

**TRADEMARKS**

See also DOMAIN NAMES

International trademark registration, **10:5**

Licences, **10:6**

National trademark registration, **10:2**

Opposition process, **10:3**

Overview, **10:1**

Pharmaceutical trade dress protection,  
**10:7**

Registration, **10:4**

Regulatory issues, **10:8**

Renewal, **10:4**

**WORLD INTELLECTUAL PROPERTY  
OFFICE (WIPO)**

Patentability of DNA, RNA and antibodies, **6:6**